Designing a CXCL8-hsa chimera as potential immunmodulator of the tumor micro-environment
By prolonging the presence of engineered chemokine mutants in the bloodstream and optimizing their stability, these strategies aim to enhance the therapeutic efficacy of CXCL8-based interventions, offering promising avenues for the treatment of several CXCL8-mediated pathologies, including cancer.
Authors
- Thomas J. Fuchs (ORCID: https://orcid.org/0000-0001-7603-8687)
- Aid Atlić
- Andreas J. Kungl (ORCID: https://orcid.org/0000-0003-3362-797X)
- Christina Trojacher (ORCID: https://orcid.org/0000-0003-1903-1686)
- Tiziana Adage (ORCID: https://orcid.org/0000-0003-2264-7924)
- Tanja Gerlza (ORCID: https://orcid.org/0000-0003-4947-9721)
- Roland Weís
Institutions
- University of Graz (AT)
- Medical University of Graz (AT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1539733
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00